Oklo Inc. has that it has signed a letter of intent to acquire Atomic Alchemy Inc., a U.S.-based radioisotope production company. The two companies announced a strategic partnership earlier this year.

TerraPower Isotopes, a subsidiary of Bellevue, Wash.–based TerraPower, announced it is now producing actinium-225 at commercial scale, making the medical isotope available to the pharmaceutical industry through weekly production runs. As a result, TerraPower Isotopes said its actinium, after further manufacturing, is now used in multiple drug developers’ radiopharmaceuticals in human clinical trials across the globe.

The only nuclear reactor in Australia has returned to power after a monthslong shutdown for planned essential maintenance and upgrades. The OPAL (for open-pool Australian light water reactor) research reactor at the Australian Nuclear Science and Technology Organization (ANSTO) campus in Sydney successfully went through the most significant engineering maintenance and upgrade project in its 17-year history.

QSA Global, a provider of radioisotope products, and Niowave, a Michigan-based producer of medical radioisotopes, announced that the companies will codevelop a scalable radium purification process using Niowave’s radium-226 processing technology to meet the demand for actinium-225, an alpha-emitter used in the treatment of cancer. According to the companies, the strategic partnership marks a significant advancement in the field of radiopharmaceutical technology, enhancing the supply chain for critical radioisotopes, including Ac-225.

Niowave uses a closed-loop cycle to produce high-purity Ac-225 and other alpha emitters from Ra-226 using a superconducting electron linear accelerator. According to the company’s website, the electron beam impinges on a photon converter to irradiate the Ra-226, inducing a photon-neutron reaction to Ra-225, which decays to Ac-225.

The Defense Advanced Research Projects Agency (DARPA) Defense Sciences Office (DSO) wants to mimic and accelerate the natural half-life decay chain of alpha-emitting radioisotopes and plans to invite proposals for experimental or theoretical research tracks under Decay on Demand—a new DARPA disruptioneering opportunity. The solicitation was published in draft form on June 27.

“What can the atom do for you, other than produce electricity from nuclear reactors?” That was the question asked and answered during an ANS Annual Conference special plenary session on June 18, introduced by ANS President Ken Petersen and organized by the ANS Young Members Group. An expert panel discussed radioisotopes and their supply chains in the context of cancer treatment, product sterilization, power for remote applications, and used nuclear fuel recycling.

Guillaume Dureau of Orano Group (left) and Orano Med’s Julien Dodet cut the ribbon on the new ATLabs Indianapolis. (Photo: Orano)

Orano Group subsidiary Orano Med, a developer of targeted alpha therapies for oncology, inaugurated its first ATLab (Alpha Therapy Laboratory) earlier this month. Located in Brownsburg, near Indianapolis, Ind., ATLab Indianapolis is an industrial-scale pharmaceutical facility dedicated to the production of lead-212–based radioligand therapies.

Targeted alpha therapy has shown to be effective in treating various oncological diseases, combining the natural ability of biological molecules to target cancer cells with the short-range cell-killing capabilities of alpha emissions generated by Pb-212. With a half-life of 10.64 hours, along with a decay product of the short-lived alpha-emitter bismuth-212, Pb-212 allows for the possible synthesis and purification of complex radiopharmaceuticals with minimum loss of radioactivity during preparation.

The development of radiopharmaceuticals has long been hampered by the difficulty of manufacturing and distribution on an industrial scale, Orano said, adding that the construction of ATLab Indianapolis is a major step toward making these new treatments available to cancer patients with high unmet needs in North America.

Europe’s first Mars rover—named Rosalind Franklin—was months away from a planned September launch when the European Space Agency (ESA) convened a meeting a few weeks after Russia’s February 2022 invasion of Ukraine. The ESA Council unanimously agreed on “the present impossibility” of working with Roscosmos as its launch partner and later decided to reboot its ExoMars mission with a new lander, new partners, and a new launch date.

Fast reactor developer Oklo, which recently went public on the New York Stock Exchange, announced on May 13 that it has signed a memorandum of understanding with Atomic Alchemy to cooperate on the production of radioisotopes for medical, energy, industry, and science applications.

The Department of Energy’s Isotope Program (DOE IP) announced last week that it would end its “active standby” capability for strontium-82 production about two decades after beginning production of the isotope for cardiac diagnostic imaging. The DOE IP is celebrating commercialization of the Sr-82 supply chain as “a success story for both industry and the DOE IP.” Now that the Sr-82 market is commercially viable, the DOE IP and its National Isotope Development Center can “reassign those dedicated radioisotope production capacities to other mission needs”—including Sr-89.

On August 2, 1946, 1 millicurie of the isotope carbon-14 left Oak Ridge National Laboratory, bound for the Barnard Free Skin and Cancer Hospital in St. Louis, Mo.

That tiny amount of the radioisotope was purchased by the hospital for use in cancer studies. And it heralded a new peacetime mission for ORNL, built just a few years earlier for the production of plutonium from uranium for the Manhattan Project.

Wisconsin-based fusion technology company SHINE Technologies has signed a long-term supply agreement with Nucleus RadioPharma for the supply of lutetium-177, a radioisotope used in cancer treatment therapies, including those in development for the treatment of neuroendocrine tumors, prostate cancer, and other solid tumors.

BWX Technologies subsidiary BWXT Medical has agreed to provide Fusion Pharmaceuticals with generators to produce actinium-225, a medical isotope used to treat cancer in clinical trials.

The Securities and Exchange Commission is suing nuclear battery developer NDB Inc., charging that the company and its chief executive officer, Nima Golsharifi, defrauded investors by making materially false and misleading statements in a company press release.

On April 10, the University of Missouri (MU) took its first formal step toward building NextGen MURR when school officials issued the request for qualifications for the project. The RFQ is a solicitation for interested companies to offer the design, engineering, licensing, environmental, and developmental services that are needed for NextGen MURR, planned to be larger and more capable than the school’s existing University of Missouri Research Reactor (MURR)—which itself has been the most powerful research reactor and most intense neutron source on any U.S. campus since it began operating in 1966.

Sherwood-Randall

The Biden administration on March 2 announced a new strategy to remove and secure certain highly radioactive materials that are used in hospitals and other civilian commercial facilities as a measure to prevent such materials from being acquired by terrorists for making “dirty bombs” or other weapons. Elizabeth Sherwood-Randall, White House assistant to the president for Homeland Security, shared the details of the National Security Memorandum to Counter Weapons of Mass Destruction Terrorism and Advance Nuclear and Radioactive Material Security (NSM19) later that same day in a discussion at the Nuclear Threat Initiative (NTI) global security organization in Washington, D.C., according to a report in the New York Times.

National strategy: Biden’s newly signed NSM 19 “integrates, in a systematic way, U.S. policies to counter the use of chemical, biological, radiological, and nuclear weapons by non-state actors; sets out unified priorities for Departments and Agencies across the Federal government; and affirms the Biden-Harris Administration’s commitment to work with state, local, tribal, international, and private sector partners on preventing, mitigating, and responding to WMD terrorism threats.”

NorthStar Medical Radioisotopes has completed construction and all equipment installation at its new facility in Beloit, Wis., to produce the medical radioisotope molybdenum-99 without the use of high-enriched uranium, the Department of Energy’s National Nuclear Security Administration announced last week.

Scientists at Lawrence Livermore National Laboratory and Oregon State University (OSU) have developed a promising new method to isolate and study some of the rarest elements on Earth. Focused first on curium, they have identified three new complexes containing curium ions and revealed the molecules’ 3D structures, as well as previously unknown features.

ANS’s August 4 online event “The New Space Race is Going Nuclear” featured several expert panelists who discussed the growing importance of nuclear technologies in space commercialization and exploration. Although nuclear energy has long played a role in space missions, participants discussed the latest exciting developments in the space nuclear field and presented their views on how increased application of nuclear technologies could fundamentally transform the ways in which both crewed and uncrewed space missions are carried out.

Accelerators and other new facilities are producing an increasing share of the radioisotopes that were once sourced solely from a handful of research reactors around the globe; demand for alpha-emitters is increasing; and the need for an ensured supply of both radioactive and stable isotopes is now heightened as many countries seek an alternative to Russian isotopes. Those are just a few of the key points that emerged from a recent webinar, “Demand and Supply of Isotopes Around the World: From Diverse Perspectives,” organized by the World Council of Isotopes, along with the Sylvia Fedoruk Canadian Centre for Nuclear Innovation and the University of Saskatchewan, the hosts of the upcoming 11th International Conference on Isotopes (11ICI).